New Users  |  Log In Contact Us



Chemotherapy Course
Download Forms
Find Other SIGs
Join A SIG
Membership Directory
SIG Annual Report
SIG Leadership
SIG Newsletter
Health Policy
Peer Reviewed Journals
EBP Resources
Terms of Use
SIG Checklist
Focus Groups

Updated December 5 2014

Articles of Interest

Download zip

Files / Folders File Size Posted By Date Posted Actions
NTR FG Goals 4 12.pdf
ONS Nutrition Focus Group
61k seisenberg 4/19/12  
Syllabus Slides.8.2011 .FINAL.ppsx
2011 IOL Powerpoint presentation on Chemotherapy
2032k seisenberg 11/29/11  
Infusion Reactions (Vogel 2010).pdf
CJON OnLine Exclusive
230k seisenberg 4/13/10  
Trastuzumab-Induced Cardiotoxicity (5MI).pdf
Five Minute Inservice version of ONF article
173k seisenberg 12/9/09  
Prevent Extravasation Injury With the Use of Antidotes.pdf
From Vesicant Chemotherapy Extravasation Antidotes and Treatments by Lisa Schulmeister, RN, MN, APRN-BC,OCN®, FAAN. CJON August 2009.
166k seisenberg 9/1/09  

December 17, 2014

Chemotherapy & Biotherapy SIG

Welcome to the Chemotherapy and Biotherapy SIG Virtual Community page. You can view resources, download policies and order sets, join in our discussions and much more. We welcome your comments and feedback. Let us know how we can better support you in your practice.

NEW forms have been added to the Download section. If you haven't been there in a while, take a look around. As always, if you have any forms/orders/policies you'd like to share, please send me an email! Webmaster.

Link to oral adherence focus group

Follow this link to the Oral Adherence Focus Group.

ONS Wants Your Perspective

Please read this article and respond to the following questions to

ONS has received inquiries about the following:

  • Cost of care for the provider (hospital, physician practice, etc) is greater at hospital-owned physician groups vs. physician-owned groups.
  • Care provided at larger institutions, including hospital-owned practices often results in higher co-pays and/or decreased choice of treatment for patients.
  • In addition to higher co-pays from larger institutions, there are patients prescribed oral oncolytics and/or oral medications for supportive care (e.g., CINV) for which insurance coverage has been denied.
  • ONS’ questions to you:
  • Are these topics consistent with experiences at your workplace? Please provide additional information (affirming or in contrast) that helps inform ONS leadership and staff
  • What is your perspective on cost-of-care barriers to care in your community

 Added per ONS staff request 11/14.

NEW! Biosimilar Survey

What have you heard about biosimilars? Not sure what they are? Take this quick survey. Information will be used to assess educational needs for Oncology Nurses.


Vote on 'Does your facility provide compensation for administering chemotherapy?'

Does your facility provide compensation for administering chemotherapy?
Yes (monetary)
Yes (non-monetary)

Vote on 'Do you infuse Vincristine IVP or IVPB?'

Do you infuse Vincristine IVP or IVPB?
A. IV Push
B. IV Piggyback

Vote on 'Does your facility require sterile procedure for accessing implanted ports?'

Does your facility require sterile procedure for accessing implanted ports?
[Defined by using sterile gloves and a mask for the RN]

Read It Before It Prints

Each month, either the Oncology Nursing Forum or Clinical Journal of Oncology Nursing releases one of its articles online in advance of the print issue. Be the first to check it out!

Read the Oncology Nursing Forum’s Accepted November advanced print exclusive article by Ellyn E. Matthews, PhD, RN, AOCNS®, CBSM, Madalynn Neu, PhD, RN, Paul F. Cook, PhD, and Nancy King, MSN, RN, CPNP®, CPON®: Sleep in Mother and Child Dyads During Treatment for Pediatric Acute Lymphoblastic Leukemia. 

Oncology Policies & Procedures CD-ROM

Oncology Policies and Procedures CD-ROM
Edited by D. Esparza

Save time and money by simplifying the process of maintaining oncology policies and procedures with
more than 60 customizable templates.
Use code POPPC10 through November 1 and save 10% on your order of the Oncology Policies
and Procedures CD-ROM!
To order, visit  or contact customer service at 866-257-4ONS.

Each year, hospitals in the United States spend thousands of dollars in labor hours writing and revising policies and procedures for program accreditation. Why start from scratch when you don’t have to? The Oncology Policies and Procedures CD-ROM from ONS saves you time and money by providing a collection of current standards of practice for use in the clinical setting. Each document has a box for custom identification and policy number insertion appropriate for your institution. Simply enter your institution’s name and customize your choices and preferences, and the policy or procedure is ready to use. You can even personalize it with your institution’s logos.

The resources on the CD are divided into six sections.
• Administration
• Electronic health records
• Human resources
• Nursing
• Safety and pharmacy
• Supportive services

Each policy contains a bibliography that gives a broad view into the latest body of work for further reading and education. The human resources section also contains job descriptions to help cancer program administrators with access to roles and duties for members of the cancer team. References to certifications and national organizations for credentialing will help administrators and hiring personnel to select the most appropriate level of staff for the position.

An additional folder includes sample forms, checklists, and consent documents that can be used as is or modified for use in the clinical area.
Don’t spend another year doing unnecessary work. Get the resources you need from a source you trust.
Institutions interested in the purchase of a multiuser license should email Pricing is based on the number of users multiplied by the regular price of the CD minus a discount based on the quantity of full-time employees identified as oncology nurses or related fields within that institution. A purchasing institution is required to provide a list of users accessing the content prior to completion of sale.

ISBN: 9781935864523 • Item INPU0645
ONS Member: $99 • Nonmember: $139
View ONS’s complete list of books at


 Added per ONS staff request 10/14.

Diversify Rounding Strategies to Improve Outcomes

Different types of rounding methods have different impacts on patient and staff satisfaction and clinical outcomes, so institutions that use a variety of techniques report the most positive results.

December's advanced print exclusive Clinical Journal of Oncology Nursing (CJON) article details how one institution implemented an assortment of rounding efforts on a 26-bed hematology/oncology unit and saw the overall trend of falls and pressure ulcers decrease from 2009 to 2013. Learn more about the specific strategies and how to implement them in your work setting, including

•             Patient rounds

•             Interdisciplinary collaborative rounds

•             Daily clinical rounds by the unit educator

•             Daily rounds by the unit manager

•             Quarterly unit rounds by senior nursing managers

•             Safety rounds by senior executives.

Read it before it prints. 


 Added per ONS staff request 10/14.

Evidence-Based Symptom Management Resources at Your Fingertips

From the team that has brought you the Putting Evidence Into Practice (PEP) resources since 2006 comes the first-ever pocket-sized book containing everything you need to immediately improve patient care.  Get the most current evidence-based information on 19 symptoms in this new, easy-to-carry guide.

Putting Evidence Into Practice: A Pocket Guide to Cancer Symptom Management

Edited by M. Irwin and L.A. Johnson

Use code PPEPC10 through November 1 and save 10% on your order of Putting Evidence Into Practice: A Pocket Guide to Cancer Symptom Management!

To order, visit or contact customer service at 866-257-4ONS.

Putting Evidence Into Practice: A Pocket Guide to Cancer Symptom Management updates the popular ONS PEP oncology symptom management resources into a portable pocket guide. Featuring the latest evidence on 19 symptom management topics, this book provides a quick-reference guide to help clinicians identify which interventions have demonstrated effectiveness against symptoms. The book is an essential tool for ensuring quality care of patients with cancer and was designed for easy carrying and referencing during direct patient care.

Each chapter outlines the nature, incidence, and impact of the symptom for patients with cancer; factors that create the highest risk; key aspects of assessment and identification of some assessment tools; intervention evidence; and suggestions for application in practice.

The following symptoms are covered.

•             Anorexia

•             Anxiety

•             Caregiver strain and burden

•             Chemotherapy-induced nausea and vomiting

•             Cognitive impairment

•             Constipation

•             Depression

•             Diarrhea (chemotherapy- and radiation-induced)

•             Dyspnea

•             Fatigue

•             Hot flashes

•             Lymphedema

•             Mucositis

•             Pain (acute, breakthrough, chronic, and refractory/intractable)

•             Peripheral neuropathy

•             Prevention of infection (general and transplant)

•             Radiodermatitis

•             Skin reactions

•             Sleep-wake disturbances


ISBN: 9781935864547 • Item INPU0650

ONS Member: $59 • Nonmember: $82.60

View ONS’s complete list of books at

Names of Targeted Therapies Names of Targeted Therapies

The Names of Targeted Therapies Give Clues to How They Work

by Deborah Christensen RN, BSN, HNB-BC


I was reading through the program of my granddaughter's dance recital and noticed that there was not a single common name in the first three groups of young dancers. It was as if their parents purposefully decided to come up with the most unique names possible. There may have been some family significance in the names, but it was hard to tell without knowing the family. This is not the case with the family names of targeted cancer drugs. Each generic name gives information on the what, how, and where of each particular drug.

In contrast to traditional chemotherapeutic agents that affect rapidly dividing cells, targeted agents are more precise in the way they fight cancer. Presently, two main families of targeted therapies exist—monoclonal antibodies and small molecule inhibitors. The ending letters (stem) of the generic names are like surnames that tell what family the drug is from and how the drug works to kill cancer cells. Monoclonal antibodies end with the stem “-mab” and small molecule inhibitors end with the stem “-ib”. The “-mab” family of targeted therapies has three distinct methods for interfering with cancer cell growth.


  1. Attach to receptors on the outside of cells to prevent the receptors from interacting with signaling molecules (e.g., growth factor receptors and growth factor interaction)
  2. Deliver radioactive molecules or toxins to the inside of the cells through attachment to cellular receptors
  3. Activate the body’s natural immune response


The “-mab” family is used when receptor targets are overexpressed on the outside of cancer cells. Conversly, the “-ib” family targets processes within the cell and therefore must be small enough in molecular weight to enter the cell and interfere with proteins on both the inside and outside of the cell. Proteins that code for growth or inhibit growth are some of the targets of this small but powerful family of drugs.

The sub stem of the generic names of the “-mabs” identifies the source where the antibodies were generated or cloned. The three most common sources are:


  1. Chimeric human-mouse—drugs ending in “-ximab” (i.e., rituximab)
  2. Humanized mouse—drugs ending in “-zumab” (i.e., bevicizumab)
  3. Fully human—drugs ending in “-mumab” (i.e., ipilimumab)


Finally, both “-mabs” and “-ibs” contain an additional stem to describe the targeted therapies bullseye. For example, the “tu” in rituximab indicates the target is the tumor, the “ci” in bevicizumab designates the circulatory system, and the “li” in ipilimumab identifies the immune system target. Some of the intracellular targets for the “-ibs” include:


  1. Tyrosine kinase inhibition—sub stem “-tinib” (i.e., imatinib)
  2. Proteasome inhibition—“-zomib” (i.e., bortezomib)
  3. Clyclin-dependent kinase inhibition—“-ciclib” (i.e., seliciclib)


The prefix of the generic names and the drug market names are where researchers and pharmaceutical companies—like the parents of the young dancers—take creative liberty.

The development of targeted therapies is expected to accelerate as new targets are identified; as a result, oncology nurses will need to stay up to date on the new medications so they can educate their patients on the way these therapies work as well as the possible side effects of the medications. Unfortunately, many people may have the idea that there are few if any side effects associated with targeted therapy. Although side effects can be less than those of standard chemotherapy, targeted therapies also affect normal cells to some degree.

So how do nurses keep up on the new therapies? Recently, ONS merged two key special interest groups (SIGs) the Targeted and Biologic Therapies SIG and the Chemotherapy SIG. The new SIG is now called the Chemotherapy and Biotherapy SIG. Another resource I found especially helpful was an animated video titled Understanding Targeted Cancer Therapies presented by the National Institute of Health.  

Identifying the source, target, and mechanism of action by uncoding the generic names of targeted therapies is fun. It is a whole lot easier than trying to figure out how parents come up with clever names for their children.


2014 SIG Leadership Workshop





CHE SIG Celebrates 25th Anniversary in 2014

The Chemotherapy & Biotherapy SIG will be celebrating their 25th Anniversary in 2014. The CHE SIG and Biotherapy SIG (separate at the beginning) were approved in August of 1989 with 42/CHE SIG charter members and 55/BIO SIG charter members. There have been many CHE/BIO SIG leaders who contributed to our history:
Biotherapy SIG                                                                                                      Chemotherapy SIG
Jacquelyn Beauregard-Dillman BA BS RN                                                                Sara Carter RN

Janet Appelbaum RN MS                                                                                        Pamela Kennedy RN

Eileen Sharp RN BSN                                                                                             Maryanne Fishman RN MS AOCN®

Nancy Moldawer RN MSN                                                                                       Mervianna Thompson RN BN MSN ANP

Janet DiJulio RN MSN                                                                                             Jeannie VanderKruik BA RN BSN OCN®

Danielle Gale ND MSN AOCNP®                                                                             Christina (Garda) White RN OCN®

Peggy Esper DNP(c) MSN ANP-BC AOCN®                                                             Kathy Wilkinson RN BSN OCN®

Paula Muehlbauer RN MSN AOCNS®                                                                      Jeanne Held-Warmkessel MSN RN AOCN® AOCNS-BC

Brenda Keith RN MN AOCNS®                                                                                Seth Eisenberg RN ASN OCN®

Kristine Abueg RN MSN OCN® CBCN®                                                                   Mildred Toth RN MS AOCN®

                                                                                                                             Myra Davis-Alston RN MSN/ED OCN® CRNI

                                                                                                                             Martha Polovich PhD RN AOCN®

2014 Chemotherapy/Biotherapy Course Changes

Learn more about the changes to the 2014 Chemotherapy/Biotherapy Course with these Frequently Asked Questions.

Television broadcast about hazardous drugs

Follow this link to view a televised investigative report about the hazards of handling chemotherapy--and why you need to take precautions.

Your Step-By-Step Guide to Quality Improvement

Have you ever read an article and said, "Okay, that's great, but how do I do this in my clinic?”

The groundbreaking supplement to the October Clinical Journal of Oncology Nursing (CJON) is here to help. 

•             Learn how a quality improvement pilot program improved patient satisfaction scores and reduced outpatient visits to the emergency room.

•             Use the new Patient Health Questionnaire-9 screening tool in your practice.

•             Read how a review of quality measures helped introduce change to practice and increased the number of patients assessed for fatigue

               (87% to 100%) and sleep-wake disturbances (15% to 80%).

•             Take advantage of a step-by-step approach to develop your own survivorship program.


Oncology nurses are obligated to help improve the quality of cancer care, and nurses at every level can have an impact. October's CJON supplement is your guide to novel and systemic approaches to assessment, screening, and interventions to adopt into practice, as well as tools, algorithms, protocols, action plans, and innovative programs to address gaps in care.

 Added per ONS staff request 10/14.

Have a suggestion for this website?

Want additional content? Have an idea for a poll? Email your ideas to the Webmaster.

Related Links

Chemotherapy SIG Newsletter
ONS Board of Directors
SIG Communiques

Powered by Readyportal Sitemap | Home

Copyright 2014 SIG. All rights reserved.